Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
943
Recruiting, any sponsor type, condition "cervical cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting943
- Completed2,327
943 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
- Studies on Tumors of the ThyroidRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001160 · 2,500 participants (planned) · Start Jun 1, 1977
Drug: 68-Gallium Dotatate · For: Hurthle Cell Thyroid Cancer; Tall Cell Variant Thyroid Cancer; Follicular Thyroid Cancer and 2 more
Sites: Bethesda, Maryland
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07591155 · 22 participants (planned) · Start May 13, 2026 · Primary completion Dec 2027
Drug: BL-ARC002 · For: Lung Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma and 1 more
Sites: Tianjin, China
- A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck CancerRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT04722523 · 40 participants (planned) · Start Jan 20, 2021 · Primary completion Jun 20, 2027
Drug: Cisplatin; Carboplatin and 4 more · For: Head and Neck Cancer; Head Cancer; Head Cancer Neck and 3 more
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT04927416 · 54 participants (planned) · Start Oct 25, 2021 · Primary completion Nov 30, 2030
Drug: 68-Gallium-DOTATATE-PET/CT · For: Metastic Thyroid Cancer
Sites: Bethesda, Maryland
Regor Pharmaceuticals Inc.Industry
NCT07524322 · 63 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2028
Drug: RGT-490 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Los Angeles, California; Boston, Massachusetts; Pittsburgh, Pennsylvania · 7 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
National Cancer Institute (NCI)NIH
NCT07667400 · 120 participants (planned) · Start Nov 25, 2026 · Primary completion Oct 1, 2036
Drug: SX-682; DTX · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Paranasal Sinus Neoplasms and 9 more
Sites: Bethesda, Maryland
AbbVieAbbVie (ABBV)
NCT07744126 · 150 participants (planned) · Start Sep 1, 2026 · Primary completion Oct 2029
Drug: Telisotuzumab Adizutecan; Pembrolizumab and 3 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Duarte, California; Newnan, Georgia; Kobe, Japan · 9 sites in all
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07338487 · 88 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 1, 2026
Drug: Nanocrystalline Megestrol Acetate Oral Suspension · For: Locally Advanced Cervical Cancer; Cachexia
Sites: Changsha, China
Wuhan KadGeno Biotechnology Co., LtdIndustry
NCT07948083 · 304 participants (planned) · Start Jan 6, 2026 · Primary completion Nov 30, 2027
Drug: KDTV001 · For: HPV (Human Papillomavirus)-Associated; HPV 16/18; HPV 52 and 1 more
Sites: Wuhan, China · 2 sites in all
- 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06492460 · 422 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 20, 2029
Drug: Drug:Cisplatin · For: Squamous Cell Carcinoma of Head and Neck
Sites: Guangzhou, China; Guilin, China; Changsha, China · 5 sites in all
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPivotal-lookingRecruiting
Bicara TherapeuticsIndustry
NCT06788990 · 650 participants (planned) · Start Jan 28, 2025 · Primary completion Apr 2028
Drug: Ficerafusp alfa; Pembrolizumab (KEYTRUDA®) and 1 more · For: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 242 sites in all
Mayo ClinicAcademic, hospital or other
NCT07783581 · 30 participants (planned) · Start Nov 4, 2026 · Primary completion Jun 1, 2030
Drug: Pembrolizumab · For: Locally Advanced Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma
Sites: Rochester, Minnesota
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT07484139 · 26 participants (planned) · Start Sep 22, 2026 · Primary completion May 2028
Drug: XL092; Pembrolizumab · For: Oral Cavity Squamous Cell Carcinoma; Head and Neck Cancer
Sites: Atlanta, Georgia; Chapel Hill, North Carolina; Philadelphia, Pennsylvania
- Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer PatientsPivotal-lookingRecruiting
West China HospitalAcademic, hospital or other
NCT07282483 · 118 participants (planned) · Start Mar 16, 2026 · Primary completion Oct 25, 2026
Drug: Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash; Placebo oral solution and mouthwash · For: Radiation-induced Oral Mucositis
Sites: Chengdu, China
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06029270 · 156 participants (planned) · Start Jul 15, 2024 · Primary completion Apr 30, 2029
Drug: Carboplatin; Cisplatin and 3 more · For: Metastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8
Sites: Dublin, California; Fremont, California; Fresno, California · 96 sites in all
National Cancer Institute (NCI)NIH
NCT05136196 · 150 participants (planned) · Start Dec 6, 2022 · Primary completion Jan 1, 2027
Drug: Cabozantinib S-malate; Nivolumab · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 and 22 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 233 sites in all
Tongji HospitalAcademic, hospital or other
NCT07947043 · 18 participants (planned) · Start Apr 22, 2025 · Primary completion Dec 2027
Drug: Autologous Tumor-Infiltrating Lymphocyte Injection · For: Recurrent or Metastatic Lung Cancer or Cervical Cancer
Sites: Wuhan, China
National Cancer Institute (NCI)NIH
NCT06064097 · 50 participants (planned) · Start Jun 25, 2024 · Primary completion Mar 31, 2027
Drug: Cisplatin; Gemcitabine and 1 more · For: Stage II Nasopharyngeal Carcinoma AJCC v8; Stage III Nasopharyngeal Carcinoma AJCC v8; Stage IV Nasopharyngeal Carcinoma AJCC v8
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 86 sites in all
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07944547 · 159 participants (planned) · Start May 26, 2025 · Primary completion Jan 2028
Drug: APL-1702; APL-1702 and 5 more · For: Cervical Intraepithelial Neoplasia Grade 2/3; Human Papillomavirus Infection
Sites: Changsha, China
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04671667 · 188 participants (planned) · Start Apr 27, 2021 · Primary completion Jun 30, 2029
Drug: Carboplatin; Cisplatin and 1 more · For: Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma and 2 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 178 sites in all
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruiting
National Cancer Institute (NCI)NIH
NCT05172245 · 46 participants (planned) · Start Sep 19, 2022 · Primary completion Jul 1, 2027
Drug: Cisplatin; Ipatasertib · For: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Carcinoma of Unknown Primary and 24 more
Sites: Tampa, Florida; Chicago, Illinois; Fairway, Kansas · 18 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.